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The First Round*Antonio Micari, MD, PHD, Giuseppe Vadalà, MDT he IDEAS (Infrapopliteal Drug-Eluting Angio-plasty Versus Stenting) trial reported bySiabilis et al. (1), in this issue of JACC: Cardio-
vascular Interventions, is an independent, single cen-
ter, self-adjudicated trial of 50 patients randomized
to receive paclitaxel drug-coated balloons (DCB) or
drug-eluting stents (DES) for treatment of long infra-
popliteal lesions. The main result of the study was
that DES usage, compared with DCB, signiﬁcantly re-
duces vessel restenosis at 6 months in the studied
population.SEE PAGE 1048We congratulate with the investigators for being
the ﬁrst to expand the research ﬁeld of infrapopliteal
DES from the typical short/focal lesions studied in
nearly all trials to date (1–6) to the notably longer
lesion lengths of 12 to 15 cm. Moreover, the study was
initiated at a time when negative results from
IN.PACT DEEP (Study of IN.PACT Amphirion Drug
Eluting Balloon vs. Standard PTA for the Treatment of
Below the Knee Critical Limb Ischemia) were not yet
available, yet the investigators chose a DCB as a
challenging control rather than the more easily
transcended standard percutaneous balloon angio-
plasty comparator. In the last 10 years, multiple in-
vestigators have consistently reported striking
reduction of angiographic restenosis and reinterven-
tion rates using DES versus percutaneous balloon
angioplasty or bare-metal stents. More recent reports
had raised hopes for the ability of DCB to reduce the
very high angiographic and clinical restenosis rates*Editorials published in the JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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paper to disclose.normally associated with use of standard percuta-
neous balloon angioplasty (7,8).
Due to its small size and innovative nature, the
IDEAS trial must be considered as a pilot, provocative,
and (appropriately enough) idea-generating study.
Although a purely lesion-related primary efﬁcacy
endpoint supports the inclusion of patients with both
critical limb ischemia (CLI) and intermittent claudica-
tion, such a mixed population makes the interpreta-
tion of major amputation difﬁcult and potentially
misleading, especially in light of the questions
regarding the safety of DCB in CLI patients recently
raised by the IN.PACT DEEP study appraisal. On the
other hand, stricter anatomical eligibility criteria, for
example, those related to severe calcium and total
occlusions, would be advisable to limit their potential
confounding role in this type of small feasibility
studies based on lesion-speciﬁc outcomes.
Whereas the use of an angiographic core laboratory
is seldom affordable in the context of independent,
investigator-initiated studies, the use of independent
adjudication (at least a third-party independent angi-
ographic reviewer) would constitute insurance against
potential bias. This derives from recent lessons
learned from DCB trials with and without core labora-
tory data analysis that reported contradictory results.
This would seem particularly imperative in view of
the nonblinded nature of the IDEAS trial. In addition,
the interpretation of sensitive angiographic endpoints
such as late lumen loss is even more challenging in
long infrapopliteal lesions in general and, especially
when balloon-based and stent-based technologies are
compared head-to-head. Loss index may be a very
appropriate adjunctive parameter to further assess the
true entity and mechanism of vessel restenosis.
However, be that as it may, binary-type measurement
of lesion-speciﬁc outcomes such as restenosis and
occlusion rates seems to support a role for DES.
The signiﬁcantly higher residual stenosis in the
DCB versus the DES arm may have contributed to the
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10586-month results. Pre-dilation, although adding the
potential for higher distal embolization, may exert a
positive effect on drug absorption that is potentially
more relevant for quick-release kinetics when using a
transiently present device such as a DCB. Moreover,
vessel preparation seems to be of non-negligible
importance in reducing paclitaxel washout during
passage of the device through narrow and calciﬁed
vessels. The 1-min inﬂation recommended by the
manufacturer for drug release would perhaps have
been better prolonged to 2 or 3 min with the aim of
obtaining a potentially more effective mechanical
dilation and consequently less residual stenosis. DCB
are to be considered as combination therapies, and
the mechanical effect of angioplasty should not be
disregarded. The DCB-to-vessel ratio and how it is to
be calculated needs clariﬁcation, as it potentially
affects the immediate results and may explain, at
least partially, the higher residual stenosis after the
procedure. Technical aspects such as pre-dilation and
sizing are critically important for DCB (and likely for
DES) treatment, hence a more detailed description
would facilitate the discussion around the acute and
expected post-procedural handicap paid by DCB, as
well as the long-term outcomes.
The investigators report a slightly better late
lumen loss in the DCB group that they attribute to
positive remodeling in 3 patients treated with
the paclitaxel balloon. Although angiography does
offer inner lumen visualization and measurement, it
should be speciﬁed whether this observation is fully
characterized as true vessel-wall ectasia versus pla-
que remodeling. Results within a different vascular
district (the superﬁcial femoral artery) reported by
Werk et al. (9) in the IN.PACT PCB arm of the
PACIFIER (Paclitaxel-Coated Balloons in Femoral
Indication to Defeat Restenosis) trial found a slightly
negative late lumen loss to be a manifestation of
plaque regression leading to luminal gain. In partic-
ular, plaque regression from post-procedure to
6 months was observed to be signiﬁcant and propor-
tional to residual stenosis after IN.PACT DCB.
In conclusion, in the vascular arena, DES technol-
ogy is a Goliath, representing a class of mature and
established devices of various brands, that, besides
their coronary labeling, have been successfullyand consistently used for below-the-knee (BTK) in-
terventions. DCB technology is a David in BTK
interventions, that is, a young and evolving technol-
ogy. It is therefore important that results and claims
from the IDEAS trial are not unnecessarily general-
ized to all DCB but remain speciﬁcally considered in
relation to IN.PACT Amphirion. At the present time,
important technological differences characterize DCB
from different manufacturers, as well as different
devices made by a particular producer. Variations in
the IN.PACT DCB used for BTK versus superﬁcial
femoral artery applications likely constitute 1 of the
concomitant causes that led to the IN.PACT DEEP trial
failure as opposed to the recently reported success
in the IN.PACT SFA (IN.PACT SFA Clinical Study for
the Treatment of Atherosclerotic Lesions in the
Superﬁcial Femoral Artery and/or Proximal Popliteal
Artery Using the IN.PACT Admiral Drug-Eluting
Balloon in a Chinese Patient Population).
CLI remains the number 1 major unmet clinical
need within the entire peripheral arterial disease
spectrum. A practicable and cost-effective clinical
solution to the burden of infrapopliteal vascular dis-
ease should continue to be eagerly investigated. The
extent and relevance of CLI vascular disease continue
to support a strong desire to develop a balloon-based,
drug-coated technology that requires no implant to
be left behind. IN.PACT Amphirion was the ﬁrst
revolution in BTK angioplasty treatment and has paid
the price of innovation and youth. The medical
community should demand and look toward ongoing
and future DCB research and DCB technology evolu-
tion to further improve vessel patency as a pre-
requisite for faster and higher wound healing and
functional limb preservation in CLI.
A second round—and more—are awaited in the duel
between David and Goliath. In this way, Time, a
knight in shining armor, will someday tell us whether
and to what extent BTK CLI outcomes can be
further improved, and David may have his revenge
respecting the end of the allegory.
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